Clinical Trial Update: Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants [Phase 2]

View source ↗

Summary

Phase 2 trial assessing 12 weeks of Sovaprevir, ACH-3102, and Ribavirin in treatment-naive genotype-1 hepatitis C patients; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ACH-3102 (ACH-3102)
• Ribavirin (ribavirin)
• Sovaprevir (sovaprevir)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2015-02-04